Available clinical evidence suggests that etofenamate is an effective therapeutic option for the management of musculoskeletal disorders, such as blunt traumas, lumbago or osteoarthrosis.

Etofenamate is indicated in painful conditions of the locomotor system when the symptomatology is localised, such as in arthropathies, myalgias, bursitis, tenosynovitis, fibrositis, neuralgias (cervical syndrome, low back pain, sciatica), contusions, sprains, and strains (associated, for example, with sports injuries).

Etofenamate has an overall efficacy and tolerability that are superior to other topical NSAIDs such as 1% indomethacin and 1% diclofenac, while being as effective as topical formulations of 2.5% ketoprofen gel and 2% ketorolac gel.

Larger and well-controlled clinical trials comparing the efficacy and safety of etofenamate with other newer topical NSAIDs are warranted.